Elaine Tomlins, Helen Winter, Anna Olsson-Brown, Jenna Robinson, Sally Long, Sarah Sheppard, Caroline Harnett, Sean Dulloo, Samantha Pickering
{"title":"皮下atezolizumab系统抗癌治疗（SACT）的分散递送：服务挑战，机遇和案例研究。","authors":"Elaine Tomlins, Helen Winter, Anna Olsson-Brown, Jenna Robinson, Sally Long, Sarah Sheppard, Caroline Harnett, Sean Dulloo, Samantha Pickering","doi":"10.12968/bjon.2025.34.Sup10b.S4","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.</p>","PeriodicalId":520014,"journal":{"name":"British journal of nursing (Mark Allen Publishing)","volume":"34 Sup10b","pages":"S4-S14"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies.\",\"authors\":\"Elaine Tomlins, Helen Winter, Anna Olsson-Brown, Jenna Robinson, Sally Long, Sarah Sheppard, Caroline Harnett, Sean Dulloo, Samantha Pickering\",\"doi\":\"10.12968/bjon.2025.34.Sup10b.S4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.</p>\",\"PeriodicalId\":520014,\"journal\":{\"name\":\"British journal of nursing (Mark Allen Publishing)\",\"volume\":\"34 Sup10b\",\"pages\":\"S4-S14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British journal of nursing (Mark Allen Publishing)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12968/bjon.2025.34.Sup10b.S4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British journal of nursing (Mark Allen Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12968/bjon.2025.34.Sup10b.S4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies.
Cancer treatment services face considerable pressures across the SACT pathway. The availability of a subcutaneous formulation of Tecentriq (atezolizumab) presents opportunities to decentralise SACT delivery to new treatment venues. With sufficient workforce training and flexibility, decentralisation could produce a lasting improvement in outcomes. Six case studies are presented highlighting successful examples of service decentralisation using subcutaneous (SC) atezolizumab, covering their impacts on patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
